Full Press Release Details
SAN DIEGO and TORONTO, March 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:
| • | 31 st Annual ROTH Conference | |
| Time: Date: Location: Format: | 8:30 a.m. PDT Tuesday, March 19, 2019 The Ritz Carlton, Laguna Niguel, CA Panel Discussion: New BTK Drugs on the Block | |
| • | Oppenheimer 29 th Annual Healthcare Conference | |
| Time: Date: Location: Live webcast: | 9:10 a.m. EDT Wednesday, March 20, 2019 The Westin Grand Central, New York, NY Link |
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor being developed to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.
For further information, please contact: For further information, please contact:
| Aptose Biosciences Greg Chow Senior Vice President, CFO 650-718-5028 gchow@aptose.com | SMP Communications Susan Pietropaolo 201-923-2049 susan@smpcommunications.com |
| LifeSci Advisors, LLC Daniel Ferry Managing Director 617-535-7746 Daniel@lifesciadvisors.com |